HepaRegenix

Tübingen, Germany · Founded 2017

Headquarters
Tübingen
Founded
2017
Business Model
B2B
Last Round
Venture RoundApr 2025
Rounds
1

About

HepaRegeniX GmbH is a clinical-stage biotechnology company based in Tübingen, Germany, founded in 2017 out of research by Prof. Lars Zender at University Hospital Tübingen together with Prof. Stefan Laufer and Dr. Wolfgang Albrecht. The company develops first-in-class small-molecule MKK4 kinase inhibitors, including lead candidate HRX-215, designed to enhance liver regeneration and treat acute and chronic liver diseases. HepaRegeniX has completed a Phase Ib study of HRX-215 and raised a €21.5 million financing round, backed by investors including Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds, Wellington Partners, and Vesalius Biocapital.

Summary

HepaRegenix is a Biotech company based in Tübingen, Germany, founded in 2017. Its most recent funding was a Venture Round in Apr 2025. Investors include Vesalius Biocapital IV, Novo Holdings A/S and Boehringer Ingelheim Venture Fund.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundApr 2025

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

HepaRegenix on Indexed.vc
<a href="https://indexed.vc/companies/heparegenix"><img src="https://indexed.vc/api/badge/company/heparegenix" alt="HepaRegenix on Indexed.vc" width="260" height="76" /></a>